NHLBI

Geisinger researchers will work with collaborators at the nonprofit FH Foundation to develop new methods for the identification and cascade testing of FH.

Nucleosome organization appears to follow two principles, according to the researchers' analyses of three different cell types.

Participants in the pilot will begin developing the capabilities required for the planned data commons, including making data transparent and interoperable.

The funding will support research projects using data from the Trans Omics for Precision Medicine program to uncover disease pathology.

Eleven new studies from the NHLBI NextGen Consortium show different uses for iPSCs to study polygenetic diseases across various systems in the human body.

The partners are developing an assay to detect minimal residual disease in leukemia patients, for use with Sellas' investigational AML drug.

Funded projects will support the agency's Trans Omics for Precision Medicine program, which is focused on heart, lung, blood, and sleep disorders.

The CCHMC will act as the coordinating center for members of the NHLBI's Cardiovascular Development Consortium and Pediatric Cardiac Genomics Consortium.

The center has already sequenced and analyzed 1,500 human genomes for the TOPMed program and will expand this effort with the new funding.